{"id":7590,"date":"2025-12-07T08:00:25","date_gmt":"2025-12-07T07:00:25","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress-resource&#038;p=7590"},"modified":"2025-12-07T14:00:14","modified_gmt":"2025-12-07T13:00:14","slug":"phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-wm","status":"publish","type":"congress-resource","link":"https:\/\/beonemedaffairs.com\/us\/congress-resource\/7590\/phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-wm\/","title":{"rendered":"Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study"},"content":{"rendered":"","protected":false},"template":"","post-tag":[760,704,686,629,703,769,691,690,596,658],"class_list":["post-7590","congress-resource","type-congress-resource","status-publish","hentry","post-tag-american-society-of-hematology","post-tag-ash","post-tag-bgb-16673","post-tag-btk","post-tag-btk-degrader","post-tag-cadance-101","post-tag-cdac","post-tag-chimeric-degradation-activation-compound","post-tag-waldenstroms-macroglobulinemia","post-tag-wm","congress_resource_type-poster","content_type-reading","disease_state-waldenstroms-macroglobulinemia","molecule-bgb-16673"],"acf":{"congress_resource_url_override":"ash-2025","congress":6819,"category":245,"prioritization":-4,"key_data_presentation":false,"key_data_presentation_only":false,"key_data_presentation_prioritization":0,"tags":[704,760,658,596,686,629,703,691,690,769],"visible_tags":[704,658,686],"content-type":246,"summary":"","text_app":"&nbsp;\r\n\r\nThis phase 1 study studied BGB-16673, an investigational drug that degrades the BTK protein, in 42 patients with Waldenstr\u00f6m macroglobulinemia who had received multiple prior therapies. The treatment was generally well tolerated. Around 60% of patients experienced grade \u22653 treatment-emergent adverse events (TEAEs), with the most common being neutropenia, diarrhea, bruising, and thrombocytopenia. No atrial fibrillation was observed. Three patients discontinued treatment due to side effects, and there were 2 deaths due to TEAEs. The overall response rate was 83%, and responses deepened over time. Clinical activity was observed regardless of patients\u2019 genetic mutations. Most patients remained on treatment, and only two deaths were related to disease progression. These results support further study of BGB-16673 in patients with Waldenstr\u00f6m macroglobulinemia.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","text":"&nbsp;\r\n\r\nThis phase 1 study studied BGB-16673, an investigational drug that degrades the BTK protein, in 42 patients with Waldenstr\u00f6m macroglobulinemia who had received multiple prior therapies. The treatment was generally well tolerated. Around 60% of patients experienced grade \u22653 treatment-emergent adverse events (TEAEs), with the most common being neutropenia, diarrhea, bruising, and thrombocytopenia. No atrial fibrillation was observed. Three patients discontinued treatment due to side effects, and there were 2 deaths due to TEAEs. The overall response rate was 83%, and responses deepened over time. Clinical activity was observed regardless of patients\u2019 genetic mutations. Most patients remained on treatment, and only two deaths were related to disease progression. These results support further study of BGB-16673 in patients with Waldenstr\u00f6m macroglobulinemia.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","table_heading":"","table":null,"faq_heading":"FREQUENTLY ASKED QUESTIONS","faq":null,"button_alt_link":"","no_post_image_preview":true,"download_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-wm.pdf","display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","vimeo_url":"","videolange":null,"fliphtml_link":"","use_pdf_instead_of_fliphtml":false,"congress_resource_abstract_link":"","congress_resource_cta_label":"See abstract","congress_resource_cta_link":"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296731","authors":[6577],"field_page_schema_override":[{"field_page_schema_override_type":"PresentationDigitalDocument","field_page_schema_override_data":"{\r\n  \"@type\": \"PresentationDigitalDocument\",\r\n  \"name\": \"Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study \u2013 BeOne Medical Affairs | US\", \r\n  \"description\": \"Discover the ASH 2025 poster with updated results from ongoing phase 1 CaDAnCe-101 study of BTK degrader BGB-16673 in WM by Constantine S. Tam et al.\",  \r\n  \"image\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/11\/ASH2025_phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-wm.jpeg\",\r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-wm\/\",  \r\n  \"associatedMedia\": {\r\n    \"@type\": \"MediaObject\",\r\n    \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296731\",\r\n    \"encodingFormat\": \"application\/pdf\"\r\n  },\r\n  \"datePublished\": \"2025-12-07\",  \r\n  \"keywords\": [\"Waldenstr\u00f6m\u2019s macroglobulinemia BTK degrader study\", \"BGB-16673 clinical efficacy\", \"phase 1 WM trial data\", \"bgb-16673 clinical trial\", \"waldenstrom macroglobulinemia clinical trials\", \"bgb-16673 in waldenstr\u00f6m macroglobulinemia\"], \r\n  \"genre\": \"Poster\",   \r\n  \"author\": {\r\n    \"@type\": \"Person\",\r\n    \"name\": \"Constantine S. Tam, MBBS (Hons), MD\"\r\n  },\r\n  \"publisher\": {\r\n    \"@type\": \"Organization\",\r\n    \"name\": \"BeOne Medicines\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/\"\r\n  },\r\n  \"about\": {\r\n    \"@type\": \"MedicalStudy\",\r\n    \"name\": \"Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study\",  \r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-wm\/\"\r\n  }\r\n}"},{"field_page_schema_override_type":"MedicalWebPage","field_page_schema_override_data":"{\r\n  \"@type\": \"MedicalWebPage\",   \r\n  \"name\": \"Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study \u2013 BeOne Medical Affairs | US\",   \r\n  \"description\": \"Discover the ASH 2025 poster with updated results from ongoing phase 1 CaDAnCe-101 study of BTK degrader BGB-16673 in WM by Constantine S. Tam et al.\",  \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-cadance-101-updated-results-of-btk-degrader-bgb-16673-in-rr-wm\/\", \r\n  \"inLanguage\": \"en-US\",\r\n  \"@logo\": {\r\n    \"@type\": \"ImageObject\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/03\/BGI2404-BeOne-Primary-Logo-RGB-M04-V01-2.svg\"\r\n  }\r\n}"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource\/7590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress-resource"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/6577"},{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6819"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/769"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/690"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/691"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/703"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/629"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/686"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/596"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/658"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/760"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/704"},{"embeddable":true,"taxonomy":"congress_resource_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress_resource_type\/245"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7590"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}